

INFORME DE BÚSQUEDA DE PATENTES PARA EL RADICADO N° 14-60426-00008-0000						
CRITERIOS PARA LA BÚSQUEDA (anexar pantallazo o reporte en PDF, junto con los booleanos utilizados)						
Palabras clave utilizadas		Human CD134 antibody, binding molecules CD134, monoclonal antibody OX40 receptor, T cell proliferation, anti – TNFRSF4, anti – ACT35.				
CLASIFICACIONES INTERNACIONALES UTILIZADAS PARA LA BÚSQUEDA		C07K 16/28				
BASES DE DATOS CONSULTADAS.						
Patentscope		Google/patents				
NCBI		ScienceDirect				
Espacenet		PatBase				
Lens						
INFORMES DE EXÁMENES REALIZADOS EN OTRAS OFICINAS (documentos patentes, literatura no patente etc...)						
Oficina	Fecha del examen o de reporte de búsqueda de documentos	Anterioridades encontradas para el examen o reportados en el examen de búsqueda(relacionarlos todos)	Reiv. afectadas	RELEVANCIA (requisito que afecta)	FUERON TENIDOS EN CUENTA PARA EL EXAMEN EN LA OFICINA COLOMBIANA	
					SI	NO
PCT INTERNATIONAL SEARCH REPORT - EPO	21/05/2013	US2011123552	1 – 7, 12 – 46, 48	Novedad/ Nivel inventivo	X	
		Santa Cruz Biotechnology, INC: "anti-OX40-receptor antibody (H-10)", January 2001 (2001-01), XP002688640.	1 – 3, 12, 13, 27, 31	Novedad		X
		Santa Cruz Biotechnology Inc.: "anti-OX40-receptor antibody (H-133)", January 2011 (2011-01), XP002688641.	1 – 3, 12, 13, 27, 31	Novedad		X
DOCUMENTOS ADICIONALES ENCONTRADOS POR EL EXAMINADOR DE ACUERDO A LOS CRITERIOS DE BÚSQUEDA.						
US2006281072						
US2010136030						
US2010196359						
WO 2004003019						
Ox40 (H-10): sc-376014; anti-OX40-receptor antibody (H-10). Santa Cruz Biotechnology, INC						
Ox40 (H-133): sc-11403; anti-OX40-receptor antibody (H-133). Santa Cruz Biotechnology Inc						
WO9942585						
US2009214560						
XIE F. <i>et al.</i> , 2010. Pathology – Research and Practice. Vol. 206. Pág. 735 – 739. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: An immunohistochemistry-based pilot study.						
Zhong W. <i>et al.</i> , 2010. OX40 induces CCL20 expression in the context of antigen stimulation: An expanding role of co-stimulatory molecules in chemotaxis						
Weinberg A. 2002. OX40: targeted immunotherapy – implications for tempering autoimmunity and enhancing vaccines						
Jensen S. 2010. Signaling Through OX40 Enhances Antitumor Immunity						
BÚSQUEDA DE SECUENCIAS						
Número de depósito / patente y N° de secuencia % de identidad						
SEQ ID NO (de la solicitud)	NCBI	The Lens	EMBL-EBI	DDJB	Genome Quest	

Búsqueda en PatBase

63) Family number: 57467194 (US2014377284A) Similar • Translate • Full-text • Status • Citations

Title: [EN] HUMANIZED ANTI-CD134 (OX40) ANTIBODIES AND USES THEREOF

Abstract: Source: US2014377284A [EN] The invention provides antibodies that specifically **bind** to human CD134. Anti-human CD134 antibodies specifically **bind** to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) **binding** domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.

Classifications: Classification Explorer


International (ipc s-a): C07K16/28 C07K16/30 (Advanced/Invention)

CPC: C07K2317/34 C07K2317/56 C07K2317/74 C07K2317/92 C07K16/30 C07K2317/565 C07K2317/75 C07K16/2878 C07K2317/24

US: 424/1174.1 435/320.1 435/334 530/387.3 530/389.7 536/23.53

Family: Family Explorer

Publication number	Publication date	Application number	Application date	Links
AU2014238546 AA	20140925	AU20140238546	20140318	
CA2907436 AA	20150916	CA20142907436	20140318	
US2014377284 AA	20141225	US20140221212	20140320	
WO14148895 A1	20140925	WO2014NL50162	20140318	



46) Family number: 49992073 (US2015132288A) Similar • Translate • Full-text • Status • Citations

Title: [EN] ANTI-CD134 (OX40) ANTIBODIES AND USES THEREOF

Abstract: Source: US2015132288A [EN] The invention provides antibodies that specifically **bind** to human CD134. Invention anti-human CD134 antibodies specifically **bind** to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) **binding** domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Invention anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.

Classifications: Classification Explorer

International (ipc s-a): A61K38/00 A61K39/395 A61P35/00 A61P35/02 A61P37/04 C07K C07K16/28 C07K16/46 C12N15/09 C12N15/13 C12N5/00 C12P21/08 G01N33/53 G01N33/68 (Advanced/Invention);

C07K (Subclass/Invention)


CPC: G01N33/6854 C07K2317/55 C07K2317/74 G01N2333/705 C07K16/2878 C07K2317/24 C07K2317/34 C07K2317/56

C07K2317/565 C07K2317/74

US: 424/133.1 424/139.1 435/29 435/320.1 435/331 435/7.21 506/9 530/387.3 530/387.9 536/23.53

Family: Family Explorer

Publication number	Publication date	Application number	Application date	Links
AU2012308155 AA	20130321	AU20120308155	20120913	



13) Family number: 30184704 (US2006281072A) Similar • Translate • Full-text • Status • Citations

Title: [EN] AGONISTIC **BINDING MOLECULES** TO THE HUMAN OX40 RECEPTOR

Abstract: Source: US2006281072A [EN] The present invention provides **binding molecules**, such as human **binding molecules**, that **bind** to and stimulate the human OX40-receptor. The invention also provides nucleic acids encoding such **binding molecules**. Methods for producing such **binding molecules** are also provided by the present invention. The **binding molecules** and nucleic acids are useful in the stimulation of human T-cells and can be used to enhance antigen-specific immune responses.

Classifications: Classification Explorer

International (ipc s-a): A61K31/00 A61K31/7088 A61K38/17 A61K39/395 A61K47/48 A61K48/00 A61K49/00 A61K51/10 A61P31/00 A61P35/00 A61P37/02 A61P37/04 C07H21/00 C07K14/705 C07K16/28 C07K16/30 C12N15/13 C12N15/63 C12N5/10 C12P21/02 C12P21/08 C12Q1/68 C40B30/06 C40B40/10 C40B50/06 G01N33/564 G01N33/566 G01N33/68 (Advanced/Invention);

A61K38/00 A61K39/00 C12N5/02 C12N5/06 C12P21/06 (Advanced/Non-invention);


C07K14/435 (Core/Invention)

International (ipc 1-7): A61K31/7088 A61K39/395 A61K47/48 A61K48/00 A61P31/00 A61P35/00 A61P37/04 C07K16/28 C12N15/13 C12P21/08 C12Q1/68 G01N33/50 G01N33/566

CPC: C07K2317/74 A61K31/00 A61K49/004F8T A61K51/1027 A61K2039/505 C07K16/2878 C07K2317/21 C07K2317/56 C07K2317/565 C07K2317/622 C07K2319/00 C07K2319/30 G01N33/564 G01N33/6893 G01N2333/70578 G01N2500/00

European: A61K31/00 A61K49/004F8T A61K51/10B28 C07K16/28R G01N33/564 G01N33/68V K61K39/505 M07K207/00 M07K316/950 M07K317/210 M07K317/560 M07K317/565 M07K317/622 M07K319/00 M07K319/30 S01N333/705R S01N500/00

US: 424/130.1 424/135.1 424/139.1 424/144.1 424/144.100S 424/154.1 424/173.1 424/173.100P 424/178.1 435/320.1 435/320.100S 435/325 435/325S 435/331 435/334 435/334S 435/5 435/5P 435/6 435/6.16 435/6.160S 435/69.1 435/69.100S 435/69.6 435/69.600S



Title: [EN] ANTAGONIST OX40 ANTIBODIES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES

Abstract: Source: US2010136030A [EN] The present invention relates to antagonist antibodies directed against human OX40 receptor (CD134) and fragments thereof, including the amino acid sequences of antagonist antibodies and the nucleic acids that encode the antibodies. Also included in the present invention are antigen binding regions (CDRs) derived from the light and/or heavy chain variable regions of said antibodies. Another aspect of the present invention is the use of anti-OX40 antagonist antibodies in the treatment of inflammatory and autoimmune diseases. The present invention also relates to humanized sequences of an antagonist antibody A10 and epitope mapping of the binding site of the antibody.

Classifications: [Classification Explorer](#)

International (ipc 8-9): A61K39/395 A61K48/00 A61P1/04 A61P1/16 A61P11/02 A61P11/06 A61P17/00 A61P17/04 A61P19/02 A61P21/04 A61P25/00 A61P25/28 A61P27/02 A61P29/00 A61P3/10 A61P37/00 A61P37/02 A61P37/06 A61P37/08 A61P43/00 A61P7/04 A61P7/06 A61P9/00 C07K16/18 C07K16/28 C12N1/15 C12N1/19 C12N1/21 C12N1/21 C12N15/09 C12N15/13 C12N15/63 C12N5/10 C12N5/12 C12P21/00 G01N33/53 (Advanced/Invention); C12P21/08 (Advanced/Non-invention); A61K39/395 A61K48/00 A61P1/00 A61P11/00 A61P17/00 A61P19/00 A61P21/00 A61P25/00 A61P27/00 A61P29/00 A61P3/00 A61P37/00 A61P43/00 A61P7/00 A61P9/00 C07K16/18 C12N1/15 C12N1/19 C12N1/21 C12N15/09 C12N15/13 C12N15/63 C12N5/10 C12N5/12 C12P21/00 G01N33/53 (Core/Invention); A61K39/395 C07K16/18 C12P21/08 (Core/Non-invention); C07K (Subclass/Invention) **International** (ipc 1-7): A61K39/00 A61K39/395 A61P29/00 A61P37/00 C07K16/18 C07K16/28 C12N15/13 C12N15/79 C12N5/12 **CPC:** C07K2317/73 C07K2317/76 C07K16/2878 A61K2039/505 C07K2317/24 C07K2317/56 C07K2317/565 C07K2317/92 C07K2319/30 **European:** C07K16/28R K61K39/505 M07K316/960 M07K317/240 M07K317/560 M07K317/565 M07K317/920 M07K319/30

PatBase - US2010136030_A1
Human OX40 (CD4) (Accession No. M1_004295)
60
325
385
240
360
420
480
540
600
660
720
780
840
900
960
1020
1084
seq (25 to 303)
seq (303 to 303)

Title: [EN] HUMAN MONOCLONAL ANTIBODY HUMAN CD134 (OX40) AND METHODS OF MAKING AND USING SAME

Abstract: Source: US2010196359A [EN] The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.

Classifications: [Classification Explorer](#)

International (ipc 8-9): A61K39/395 A61P37/00 A01K67/027 A61P1/00 A61P1/04 A61P13/12 A61P17/06 A61P19/02 A61P21/00 A61P25/00 A61P25/28 A61P29/00 A61P3/10 A61P35/00 A61P37/02 A61P37/06 C07K16/00 C07K16/16 C07K16/28 C12N1/15 C12N1/19 C12N1/21 C12N15/02 C12N15/09 C12N15/13 C12N5/10 C12N5/20 C12P21/08 (Advanced/Invention); A61K39/395 A61P37/06 C07K16/28 C12N15/13 (Advanced/Non-invention); A01K67/027 A61K39/395 A61P1/00 A61P13/00 A61P17/00 A61P19/00 A61P21/00 A61P25/00 A61P29/00 A61P3/00 A61P37/00 C07K16/00 C07K16/18 C12N15/09 C12N15/13 C12N5/10 C12N5/20 (Core/Invention) **CPC:** C07K16/2878 A61K2039/505 C07K2317/21 C07K2317/30 C07K2317/71 C07K2317/732 C07K2317/76 C07K2317/92 C12N2799/026 **European:** C07K16/28R K61K39/505 M07K317/210 M07K317/300 M07K317/710 M07K317/732 M07K317/760 M07K317/920 M12N799/02A66 **US:** 424/133.1 424/133.100P 424/139.1 424/142.1 424/142.100S 530/387.3 530/387.300S 530/387.9 530/387.900S 530/388.1 530/388.15 530/388.150S 530/388.22

Family: [Family Explorer](#)

